Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
Julius Keyl(Essen University Hospital), Jens Kleesiek(Essen University Hospital), Stefan Kasper(Essen University Hospital), Jan Egger(Graz University of Technology), René Hosch(Essen University Hospital), Grégoire Montavon(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Alexander Roesch(Essen University Hospital), Philipp Jurmeister(German Cancer Research Center), Stephan Lang(Essen University Hospital), Sebastian Bauer(Science for Life Laboratory), Johannes Haubold(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Anja Welt(Essen University Hospital), Martin Schüler(German Cancer Research Center), Rainer Kimmig(Essen University Hospital), Ulrich Sure(University of Duisburg-Essen), Hideo A. Baba(Essen University Hospital), Moon Kim(Essen University Hospital), Frederick Klauschen(Charité - Universitätsmedizin Berlin), Tienush Rassaf(University Hospitals of the Ruhr-University of Bochum), Martin Stuschke(Essen University Hospital), Jens T. Siveke(German Cancer Research Center), Sven Koitka(Essen University Hospital), Klaus-Robert Müller(Oral Roberts University), Gabriel Dernbach(Heidelberg University), Nikolaos E. Bechrakis(Essen University Hospital), Boris Hadaschik(Essen University Hospital), Michael Forsting(University of Duisburg-Essen), Philipp Keyl(Humboldt-Universität zu Berlin), Marcel Wiesweg(Essen University Hospital), Matthias Totzeck(Essen University Hospital), Felix Nensa(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Liliana H. Mochmann(Ludwig-Maximilians-Universität München), Alexander Brehmer(Essen University Hospital), Ken Herrmann(Essen University Hospital), Martin Glas(Essen University Hospital), Dagmar Führer‐Sakel(Klinik und Poliklinik für Urologie), Viktor Grünwald(Deutsche Schmerzgesellschaft)
Cited by 48
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k